---
title: Opioid-Free Intraoperative Anesthesia (OFIA) With ACB + IPACK
version: 1.4
last-updated: 2025-12-14
---

# Opioid-Free Intraoperative Anesthesia (OFIA) With ACB + IPACK  
**Protocol 1 – Preferred First-Line rTKA Pathway**

---

## 1. Purpose
Provide a standardized **first-line** opioid-free intraoperative anesthesia (OFIA) pathway for robot-assisted total knee arthroplasty (rTKA) using **adductor canal block (ACB)** and **IPACK**. This protocol optimizes analgesia, minimizes opioid exposure, reduces PONV, preserves quadriceps strength, and supports ERAS goals including **POD 0 ambulation**.

Protocols are **informed by** ERAS arthroplasty guidance (2019–2024 updates), ASA/APSF perioperative safety guidance (2024), and ASRA/ESRA regional anesthesia principles (2024–2025), but **do not replace** institutional policy or attending anesthesiologist judgment.

> **Educational Use Only – Not a Clinical Guideline**  
> - All doses represent **typical adult ranges** and must be individualized  
> - Pathway selection remains **attending-dependent**  
> - Frail, elderly, OSA, cardiac, renal, or hepatic impairment requires dose modification  
> - Conservative guardrails are intentional to reduce misuse and adverse-event risk  

---

## 2. Preoperative Phase

### 2.1 Patient Assessment
- Standard preanesthetic evaluation and airway assessment  
- Review prior anesthesia records and complications (PONV, delirium, difficult airway)  
- Identify risk factors: OSA, frailty, cognitive impairment, cardiovascular disease  
- Assess opioid tolerance or chronic opioid use ensure continuation of baseline regimen per institutional policy  
- **Confirm suitability for deep peripheral nerve blocks (ACB/IPACK)**  
- **Screen for ketamine caution contexts:** advanced age, frailty, hemodynamic instability, tachyarrhythmia risk, catecholamine-depleted physiology, severe psychiatric disease  

### 2.2 Anticoagulation and Block Safety (ASRA/ESRA 2024–2025)
For this repository, **ACB and IPACK are treated as deep peripheral blocks** and require **ASRA/ESRA-consistent timing with institutional policy adherence**.

- Anticoagulation and antiplatelet regimen fully reconciled  
- Last dose timing documented  
- Renal function documented where relevant (e.g., DOAC clearance)  
- Block timing verified using **current institutional tables aligned with ASRA/ESRA guidance**  
- If timing criteria are not met → **do not perform blocks**; proceed with OFIA block-free or alternative pathway  

> Anticoagulation timing is **agent-, dose-, renal function-, and procedure-dependent**.  
> Do not hard-code timing outside institutional guidance.

---

### 2.3 Preoperative Medications (ERAS-Informed)
- **Acetaminophen 1 g PO** (30–60 min pre-op)  
- **Celecoxib 400 mg PO** (1–2 hours pre-op; meloxicam 15 mg alternative per policy)  
- **Dexamethasone 8–10 mg IV** after IV placement  
- **Scopolamine patch 1.5 mg** for *high PONV risk only*  
- **Avoid routine gabapentinoids** (ASA/APSF safety signal: sedation, delirium, respiratory risk)  
- *Midazolam reserved for block placement anxiolysis*

---

## 3. Regional Blocks (Ultrasound-Guided – Required for Protocol 1)

### 3.1 Pre-Block Anxiolysis
- **Midazolam 1–2 mg IV**  
  - Use **0.5–1 mg** in elderly, OSA, or frail patients  
  - Avoid oversedation  
  - Consider omitting additional midazolam at induction if adequate anxiolysis achieved

### 3.2 Adductor Canal Block (ACB)
- **Ropivacaine 0.2–0.25%, 20–30 mL**  
- Subsartorial approach targeting the vastoadductor canal  
- Incremental injection with frequent aspiration and ultrasound-confirmed spread  

### 3.3 IPACK Block
- **Ropivacaine 0.2–0.25%, 15–20 mL**  
- Ultrasound-guided injection between posterior capsule and popliteal artery  
- Incremental injection; avoid intravascular or intraneural placement  

### 3.4 Documentation
- Total local anesthetic dose (mg)  
- Conservative reference ceiling: **~3 mg/kg ropivacaine equivalent** (institution-dependent)  
- Block type, laterality, volume, concentration  
- Patient tolerance and block quality  
- Confirmation of quadriceps motor preservation (motor-sparing intent)

### 3.5 Safety
- **Lipid emulsion 20% immediately available**  
- LAST protocol visible and accessible  
- Monitoring during and after block placement

---

## 4. Induction

### 4.1 Primary Induction (Propofol-Based)
- **Propofol 1.5–2 mg/kg IV**  
- **Rocuronium 0.6–1.0 mg/kg IV**  
- **Midazolam 0–0.5 mg IV** *only if needed* (often omitted if already dosed for blocks)

### 4.2 Ketamine (Optional Analgesic Adjunct)
- **Ketamine 0.2–0.5 mg/kg IV** (sub-anesthetic dosing; titrate to effect)  
- Favor lower end in elderly, frail, or hemodynamically fragile patients  

**Use caution, reduce dose, or omit** in:
- Hemodynamic instability or catecholamine-depleted physiology  
- Significant tachyarrhythmia risk  
- Frailty or high delirium-risk phenotype  
- Active psychosis or unstable psychiatric disease  

**EEG caveat:** Ketamine may elevate BIS and alter EEG dynamics. Avoid titrating hypnotic depth to BIS alone after administration.

### 4.3 Optional Adjunct Initiation
- **Dexmedetomidine infusion (no routine loading dose):**  
  - Start **0.2–0.4 mcg/kg/hr** (lower end in elderly/frail)  
- **Magnesium sulfate 30–50 mg/kg IV** over 15–20 minutes  
  - Avoid if **CrCl <30 mL/min** or myasthenia gravis

---

## 5. Maintenance

### 5.1 Primary Maintenance Strategy
- **Propofol TIVA 75–150 mcg/kg/min** (**default maintenance backbone**)  
- **Optional sevoflurane ~0.5–1.2 MAC** may be added selectively (hybrid or transition strategy)

### 5.2 Adjuncts (Selection-Dependent)
- **Dexmedetomidine 0.2–0.7 mcg/kg/hr**  
  - Favor **0.2–0.4 mcg/kg/hr** in elderly/frail  
- **Ketamine infusion 0.1–0.2 mg/kg/hr** (optional)  
- Magnesium as dosed above if selected

### 5.3 Hemodynamic Management
- Target **MAP ≥65 mmHg** (individualize for CAD or cerebrovascular disease)  
- Dex-related bradycardia or hypotension:
  - Reduce or stop infusion  
  - **Glycopyrrolate 0.2–0.4 mg IV** if symptomatic per institutional practice

### Key Principle
**Zero intraoperative opioids** unless conversion is required for patient safety.

---

## 6. Emergence

### 6.1 Pre-Emergence (10–15 Minutes Prior)
- Taper or stop dexmedetomidine as tolerated  
- Plan discontinuation of ketamine infusion if used

### 6.2 At Skin Closure
- Stop ketamine infusion (if used)  
- Reduce propofol toward emergence dosing  
- If sevoflurane used, taper toward **~0.5–0.7 MAC**

### 6.3 Reversal and PONV Prophylaxis
- **Ondansetron 4 mg IV**  
- **Sugammadex 2 mg/kg** (TOF ≥2 but <0.9)  
- **Sugammadex 4 mg/kg** for deep block

### 6.4 Extubation Criteria
- Awake and follows commands  
- RR 10–20, TV >5 mL/kg  
- SpO₂ >92%  
- TOF ratio ≥0.9  
- Hemodynamically stable

---

## 7. Postoperative Phase

### 7.1 Expected Pain Profile
- **NRS 0–3** for first 12–18 hours  
- If NRS ≥4:
  - Assess block quality and tourniquet contribution  
  - Evaluate for surgical complications

### 7.2 Scheduled Multimodal Analgesia
- **Acetaminophen 1 g PO/IV q6h** (max 4 g/day)  
- NSAID options (institutional policy):
  - Celecoxib 200 mg PO q12h  
  - Ketorolac 15 mg IV q6h  
  - Meloxicam 15 mg PO daily  

### 7.3 Rescue Analgesia (Stepwise)
1. **Ketamine 0.1–0.15 mg/kg IV q10–15 min** (max ~3 doses)  
   - Reduce or omit in frail, elderly, unstable, or tachyarrhythmia-prone patients  
2. **Hydromorphone 0.2 mg IV** only if inadequate response and clinically appropriate  
   - Enhanced respiratory monitoring required

### 7.4 Mobilization
- POD 0 ambulation typically within **4–6 hours**  
- Quad-sparing block supports safe early mobility

### 7.5 Block Duration and Transition
- ACB + IPACK duration: **~12–18 hours** (variable)  
- Ensure oral multimodal regimen in place before block resolution

---

## 8. Notes

### Clinical Advantages
- ERAS-aligned, opioid-minimizing strategy  
- Low PONV profile  
- Motor-sparing regional analgesia  
- Supports early mobilization and discharge readiness

### Ideal Patient Population
- Opioid-naïve or opioid-sensitive patients  
- High PONV risk  
- Patients prioritizing early mobility  
- Older adults when opioid minimization is advantageous (with conservative adjunct dosing)

### Contraindications
- Patient refusal  
- Anticoagulation outside ASRA/ESRA windows  
- Infection at injection site  
- Amide local anesthetic allergy  
- Adjunct contraindications (non-exhaustive):
  - Active psychosis (ketamine context-dependent)  
  - Significant hemodynamic instability  
  - **CrCl <30 mL/min** (magnesium avoidance)  
  - Advanced AV block without pacemaker (dexmedetomidine caution)

---

## 9. References
See: **../../07_References_Evidence_2024.md**